We present a previously undocumented complication of dystrophic calcification of the prostate after cryotherapy. An 87-year-old male presented with recurrent lower urinary tract infections and was found to have an obstructing large calcified mass in the right lobe of the prostate. Subsequently, he underwent transurethral resection of the prostate (TURP) and bladder neck with laser lithotripsy to remove the calculus. We propose that chronic inflammation and necrosis of the prostate from cryotherapy resulted in dystrophic calcification of the prostate. As the use of cryotherapy for the treatment of localized prostate cancer continues to increase, it is important that clinicians be aware of this scenario and the technical challenges it poses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273508 | PMC |
| http://dx.doi.org/10.1155/2014/471385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Recurrence of Tracheobronchial Papillomatosis Following Prostate Cancer Diagnosis.
Cureus
November 2024
Department of Respiratory Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, GRC.
Recurrent respiratory papillomatosis (RRP) is a challenging disease to manage, due to its highly recurring nature and the lack of a definitive treatment. It is characterized by the presence of benign papillomatous lesions caused by the human papillomavirus (HPV), which can pose a threat to the patient's airway patency and restrict their breathing ability. We present the case of a 64-year-old patient with a history of papillomas in the trachea and bronchi, treated with endobronchial cryotherapy.
View Article and Find Full Text PDFErectile dysfunction associated with prostate cancer treatment and therapeutic advances: a narrative review.
Transl Androl Urol
November 2024
Department of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Background And Objective: The treatment of prostate cancer (PCa) often comes with the risk of erectile dysfunction (ED). As therapeutic technologies continue to advance, the incidence of ED and its treatment methods are also evolving. This paper aimed to provide a comprehensive analysis of the latest developments in PCa treatment, with a particular focus on its relationship with ED, and to review current innovative strategies for ED treatment.
View Article and Find Full Text PDFManagement strategies for radio-recurrent prostate cancer: a comprehensive review.
Transl Cancer Res
November 2024
Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following radiotherapy necessitates a nuanced management strategy that considers disease stage and aggressiveness, patient health status, and prior treatment modalities. Androgen deprivation therapy (ADT), a cornerstone in the management of regional or distant relapse, often initiates the therapeutic cascade, effectively suppressing tumor growth by targeting androgen signaling.
View Article and Find Full Text PDFProstatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials.
Curr Opin Urol
November 2024
Department of Urology.
Article Synopsis
- Oligometastatic prostate cancer (OMPCa) is an intermediate stage of cancer between localized and widespread disease, traditionally treated with androgen deprivation therapy (ADT) but now also considered for local therapies like cytoreductive prostatectomy (CRP) and radiotherapy.
- Recent studies suggest that CRP may be beneficial for some OMPCa patients, and ongoing trials are exploring its safety and effectiveness, alongside findings supporting the use of radiotherapy and ADT.
- There is still limited evidence for focal therapies and cryotherapy, highlighting the need for more clinical trials to better understand treatment options and suitability for patients with OMPCa.
Prostate ablation for the management of localized prostate cancer.
Urol Oncol
November 2024
Division of Biostatistics and Bioinformatics, University of Cincinnati College of Medicine, Cincinnati, OH.
Purpose: To evaluate the oncological and genitourinary outcomes of various forms of prostate ablation for localized prostate cancer.
Methods: A prospectively managed database included men with localized prostate cancer who underwent prostate ablation during January 2018-August 2023. Patients received either whole or partial-gland ablation using 1 of 3 energy modalities: cryotherapy, High Intensity Focused Ultrasound (HIFU), or Irreversible electroporation (IRE).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!